What is Roth Capital’s Forecast for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities research analysts at Roth Capital increased their FY2024 EPS estimates for Tenax Therapeutics in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will post earnings per share of ($1.16) for the year, up from their previous estimate of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

Several other equities research analysts have also recently issued reports on the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. William Blair assumed coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. Finally, Leerink Partners assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Performance

Shares of TENX stock opened at $4.83 on Monday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $33.44. The firm’s 50 day moving average is $4.02 and its 200 day moving average is $3.70.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the 3rd quarter valued at $101,000. Vestal Point Capital LP bought a new stake in shares of Tenax Therapeutics during the 3rd quarter valued at $288,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the 3rd quarter valued at $173,000. 1.67% of the stock is currently owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.